Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease
Mario Hero, Nadja Grozdanić, Romana Brnić Andrić, Eliša Papić, Olivio Perković, Vladimira VuletićAbstract
Background
Continuous subcutaneous foslevodopa/foscarbidopa (LDp/CDp) provides 24‐h delivery of levodopa‐carbidopa prodrugs for advanced Parkinson's disease. Real‐world 1‐year European data remain limited.
Objectives
To characterize 1‐year changes in motor, non‐motor, autonomic, quality‐of‐life and sleep outcomes, and in concomitant therapy.
Methods
Retrospective single‐center observational study of 32 patients initiated on LDp/CDp between April 2024 and January 2026.
Results
Twenty of 32 patients (62.5%) completed 1‐year follow‐up. MDS‐UPDRS Part III improved by 30.3%, Part IV by 36.0% and Part II by 13.2% (all significant); non‐motor and autonomic totals were unchanged. Quality of life improved ( p = 0.040), driven by bodily discomfort. Levodopa‐equivalent dose rose by 31.7% while oral dopamine agonist use fell from 70% to 25% ( p = 0.004).
Conclusions
One year of LDp/CDp was associated with substantial motor benefit and improved quality of life, achieved with higher levodopa equivalent and reduced dopamine agonist use.